Drugs / 129Xenon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01280994 | Jan 2011 → Dec 2030 expected | interstitial lung disease | Bastiaan Driehuys | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 129Xenon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01280994 ↗ |
| Modality | Diagnostic / imaging agent | “only an inhaled gas contrast agent” NCT01280994 ↗ |
| Route | Inhaled | “only an inhaled gas contrast agent” NCT01280994 ↗ |